AM 211

Drug Profile

AM 211

Alternative Names: AM211

Latest Information Update: 16 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amira Pharmaceuticals
  • Developer Panmira Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Small molecules
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Asthma; Chronic obstructive pulmonary disease; Hypersensitivity

Most Recent Events

  • 16 Mar 2016 No recent reports on development identified - Phase-I for Chronic obstructive pulmonary disease in USA (PO)
  • 16 Mar 2016 No recent reports on development identified - Preclinical for Hypersensitivity in USA (PO)
  • 16 Mar 2016 No recent reports on development identified - Phase-I for Asthma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top